You are in: eMedicine Specialties > Neurosurgery > MEDICAL TOPICS HemangioblastomaArticle Last Updated: Apr 13, 2006AUTHOR AND EDITOR INFORMATIONSection 1 of 11
  Author: Konstantin V Slavin, MD, Associate Professor, Department of Neurosurgery, University of Illinois at Chicago; Head, Section of Stereotactic and Functional Neurosurgery, University of Illinois at Chicago Konstantin V Slavin is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, American Pain Society, American Society of Stereotactical and Functional Neurosurgery, and Congress of Neurological Surgeons Editors: Duc Hoang Duong, MD, Associate Professor, Director of Neuroscience Physician Assistant Program, Departments of Neurological Surgery and Neuroscience, Epilepsy Center, Charles R Drew University; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Ryszard M Pluta, MD, PhD, Associate Professor, Neurosurgical Department Medical Research Center, Polish Academy of Sciences at Warsaw, Poland; Senior Researcher, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH; Herbert H Engelhard III, MD, PhD, Director, UIC Neuro-Oncology Program, Chief, Division of Neuro-Oncology, Associate Professor, Department of Neurosurgery, University of Illinois at Chicago; Allen R Wyler, MD, Former Medical Director, Northstar Neuroscience, Inc Author and Editor Disclosure Synonyms and related keywords: hemangioblastoma, Lindau tumor, Lindau's tumor, capillary hemangioblastoma, vascular neoplasm, meningeal tumor, intracranial neoplasm, intracranial tumor, vascular tumor, von Hippel-Lindau disease, VHL disease INTRODUCTIONSection 2 of 11
  In 1928, Cushing and Bailey introduced the term hemangioblastoma (Cushing, 1928). It refers to a benign vascular neoplasm that arises almost exclusively in the central nervous system. According to the World Health Organization classification of tumors of the nervous system, hemangioblastomas are classified as meningeal tumors of uncertain origin (Rubinstein, 1972; Gonzales, 1995). History of the ProcedureSince its original description, hemangioblastomas have been found in multiple regions of the central nervous system. Predominant involvement of the cerebellum and the spinal cord was noted, but true incidence of this tumor was not discovered until the recent increased availability of noninvasive diagnostic imaging modalities, particularly magnetic resonance imaging. This, in addition to significant improvement in surgical approaches and microsurgical technique, have made hemangioblastoma, although dangerous, a potentially treatable and curable disease. FrequencyIncidence and location Hemangioblastomas are rare, and according to various series, they account for 1-2.5% of all intracranial neoplasms (Zulch, 1986; Neumann, 1989). Most hemangioblastomas are located in the posterior cranial fossa; in that region, hemangioblastomas comprise 8-12% of neoplasms. Hemangioblastoma is the most common primary adult intraaxial posterior fossa tumor (Constans, 1986). Cerebellar hemangioblastomas are frequently referred to as Lindau tumors because Swedish pathologist Arvid Vilhelm Lindau first described them in 1926 (Lindau, 1926). The second most common location of hemangioblastomas is the spinal cord (Yasargil, 1976; Murota, 1989; Fischer, 1996; Roonprapunt, 2001), where the frequency ranges from 2-3% of primary spinal cord neoplasms to 7-11% of spinal cord tumors. This tumor's occurrence in other locations, such as the supratentorial compartment (Adegbite, 1983; Goto, 2001; Peker, 2005), the optic nerve (Kerr, 1995), the peripheral nerves (Giannini, 1998), or the soft tissues of extremities (Patton, 2005) is extremely rare. Sex and age distribution Hemangioblastomas are more common in men than in women. In most clinical series, the male-to-female ratio is approximately 2:1. Although hemangioblastomas may develop at any age, they rarely affect children; the usual age at diagnosis is between the third and fifth decades. von Hippel-Lindau disease Most hemangioblastomas arise sporadically. However, in approximately one quarter of all cases, they are associated with von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary syndrome that includes retinal angiomatosis, central nervous system hemangioblastomas, and various visceral tumors most commonly involving the kidneys and adrenal glands. This syndrome is classified as a phakomatosis, although it does not include any cutaneous manifestations. The syndrome has variable penetrance, but its dominant mode of transmission compels performing at least a screening of family members of patients diagnosed with VHL disease. In some patients with VHL disease, hemangioblastomas may produce erythropoietinlike substances, resulting in polycythemia at the time of diagnosis. EtiologyEtiology of the hemangioblastoma is obscure, but its presence in various clinical syndromes may suggest an underlying genetic abnormality. The genetic hallmark of hemangioblastomas is the loss of function of the von Hippel-Lindau (VHL) tumor suppressor protein (Zagzag, 2005). PathophysiologyUpon gross examination, hemangioblastomas are usually cherry red in color. They may include a cyst that contains a clear fluid, but solid tumors are as common as cystic ones. The tumor usually grows inside the parenchyma of the cerebellum, brain stem, or spinal cord; it is attached to the pia mater and gets its rich vascular supply from the pial vessels. However, extramedullary and extradural hemangioblastomas also have been described (Agostinelli, 2004). ClinicalThe clinical presentation of hemangioblastomas usually depends on the anatomical location and growth patterns. Cerebellar lesions may present with signs of cerebellar dysfunction, such as ataxia and discoordination, or with symptoms of increased intracranial pressure due to associated hydrocephalus. In general, intracranial hemangioblastomas present with a long history of minor neurological symptoms that, in most cases, are followed by a sudden exacerbation, which may necessitate immediate neurosurgical intervention. Patients with spinal cord lesions most frequently present with pain, followed by signs of segmental and long-track dysfunction due to progressive compression of the spinal cord. Patients with VHL disease may present with ocular or systemic symptoms due to involvement of other organs and systems. The polycythemia that may develop in some patients with hemangioblastomas usually is clinically asymptomatic. Spontaneous hemorrhage is possible in both intraspinal and intracranial hemangioblastomas (Glasker, 2005), but this risk is low and tumors smaller than 1.5 cm carry virtually no risk of spontaneous hemorrhage. INDICATIONSSection 3 of 11
In many cases, symptoms caused by the growth of the neoplasm itself may be an indication for surgical intervention. In others, symptomatic obstruction of the cerebrospinal fluid (CSF) pathways may necessitate the operation. Asymptomatic lesions that sometimes are encountered in patients with multiple hemangioblastomas may be safely observed with frequent MRI scans to rule out tumor enlargement. RELEVANT ANATOMYSection 4 of 11
Presence of a hemangioblastoma rarely, if ever, alters normal anatomy. In choosing the appropriate surgical approach to the tumor, one must take into consideration the position of the mass, presence (or absence) of a large cystic component, associated hydrocephalus and surrounding edema, and the eloquence of neighboring neural and vascular structures. In most cases, cerebellar lesions may be removed through a suboccipital craniectomy, whereas spinal lesions are best addressed from a posterior direction through a laminectomy approach. CONTRAINDICATIONSSection 5 of 11
As always, surgical resection should be offered to the patient unless the risk of operation outweighs its potential benefits. Acute anticoagulation, the presence of active systemic infection, and severe medical problems that would make general anesthesia too risky generally are considered contraindications for an elective neurosurgical operation. However, the decision should be made on an individual basis. WORKUPSection 6 of 11
Lab Studies
Imaging Studies
Other Tests
Histologic FindingsHistologically, hemangioblastomas are vascular neoplasms. In addition to relatively normal-appearing endothelial cells that line capillary spaces, hemangioblastomas have 2 distinct cellular components that may occur in the same tumor in different proportions. The first type is small, perivascular, endothelial cells that have dark compact nuclei and sparse cytoplasm. Cells of the second type contain multiple vacuoles and granular eosinophilic cytoplasm rich in lipids. These stromal cells may show some nuclear pleomorphism, but mitotic figures rarely are seen. The exact histogenetic origin of stromal cells is unknown, but the latest studies indicate that they may represent a heterogeneous population of abnormally differentiating mesenchymal cells of angiogenic lineage, with some morphological features of endothelium, pericytes, and smooth-muscle cells (Lach, 1999). Two histological subtypes (cellular and reticular) have been described in primary hemangioblastomas of the central nervous system and have been found to correlate with the probability of tumor recurrence (Hasselblatt, 2005). The reticular subtype is more commonly encountered; the cellular subtype is associated with higher probability of recurrence. No histologic grading system exists for hemangioblastomas. StagingNo established histologic grading system exists for hemangioblastomas. TREATMENTSection 7 of 11
Medical therapyBecause hemangioblastomas are benign tumors and generally are not invasive in nature, they may be cured by surgical excision. Therefore, surgical resection is considered a standard of treatment and should be offered to the patient unless the risk of operation outweighs its potential benefits (Yasargil, 1976; Constans, 1986; Murota, 1989; Symon, 1993; Fischer, 1996; Roonprapunt, 2001; Zhou, 2005). Other therapeutic modalities include endovascular embolization of the solid component of the tumor (Eskridge, 1996; Takeuchi, 2001), which may decrease the vascularity of the tumor and lower blood loss during its resection, and stereotactic radiosurgery of the tumor using either a linear accelerator (Chang, 1998) or a Gamma Knife (Niemela, 1996; Patrice, 1996; Pan, 1998). Antiangiogenic treatment of hemangioblastoma has also been recently described (Schuch, 2005). Surgical therapySurgical treatment of hemangioblastomas is total resection, with the main goal being the preservation of surrounding neural tissue. The tumors usually are well demarcated from the surrounding brain or spinal cord, but this border of separation does not contain any particular membrane or capsule. The surgical approach must be wide enough to avoid compression of the healthy tissues during retraction. Thorough evaluation of preoperative imaging studies is the key to the safest possible exposure of the tumor. In addition to MRI and CT scans, review the angiography findings to identify the principal blood supply to the tumor mass. Preoperative detailsPrior to surgery, patients should undergo adequate medical evaluation and complete neural axis imaging. Patients and their families must be informed about the risks and possible complications of surgery, particularly the potential for neurological deterioration. Intraoperative detailsThe tumor is usually easy to visualize because of its reddish-colored solid component and the yellow fluid inside the cyst. If the cyst is present, it may be emptied by cutting the covering pial membrane or by aspirating the cystic contents using a syringe with a short small-caliber needle. Decompression of the cyst allows for improved delineation of the interface between the tumor and the brain or spinal cord. The surface of the tumor may be coagulated with wide bipolar forceps; however, avoid penetration of the tumor itself because of its extreme vascularity and difficulties with hemostasis. Try to dissect the tumor circumferentially by careful coagulation and cutting the small feeding vessels and adhesions between the tumor and the surrounding brain or spinal cord and by putting cottonoid strips into the developing plane to avoid direct pressure on the brain or spinal cord tissue. Once the feeding vessels are identified, they are coagulated and cut. Try to coagulate the arterial feeders prior to the draining veins, but this is not as crucial as it is in arteriovenous malformations. After the tumor is totally removed, the raw surface of the brain or spinal cord remains relatively bloodless, and the oozing blood stops after a few minutes of gently packing the resection cavity with wet cotton balls, avoiding the need for additional coagulation. If an associated hydrocephalus exists, it must be addressed separately, usually by means of external ventricular drainage (EVD) prior to tumor resection. After the tumor is removed, the need for permanent shunt placement may be determined by the patient's response to EVD clamping. In most cases, an intramedullary syrinx does not require a separate drainage procedure because it usually resolves after tumor removal. Postoperative detailsIn regards to general surgical management, having blood products available for transfusion is very important because the vascular character of hemangioblastomas may result in serious intraoperative blood loss. Additionally, anesthesia for patients with VHL disease may be quite challenging due to the presence of associated renal and endocrine dysfunction. Follow-upFollow-up care for patients with hemangioblastomas should include regular neurological and imaging checks to confirm the absence of tumor recurrence and/or development of distant lesions. COMPLICATIONSSection 8 of 11
With an adequate preoperative workup, most complications of surgery for hemangioblastoma may be avoided. Meticulous maintenance of hemostasis, attention to minor details, and great respect for neural and vascular elements may significantly decrease the risk of postoperative complications. The main emphasis, as usual, should be placed on preventing complications rather than on treatment. OUTCOME AND PROGNOSISSection 9 of 11
Long-term results of hemangioblastoma management generally are favorable. Advancement of neuroimaging methods, improvements in microsurgical technique, and the addition of preoperative embolization have significantly lowered morbidity and mortality associated with hemangioblastoma surgery. Subarachnoid dissemination of hemangioblastomas is extremely rare (Hande, 1996), and local recurrences after complete tumor resection seem to be more frequent in patients with von Hippel-Lindau (VHL) disease, in patients diagnosed at a young age, and in patients with multiple hemangioblastomas. The recurrence rate varies in different surgical series but generally remains less than 25%. Recently, histological subtype was found to correlate with a probability of hemangioblastoma recurrence, with a 25% recurrence rate in cellular subtype and an 8% recurrence rate in reticular subtype (Hasselblatt, 2005). Conclusion Hemangioblastomas are benign tumors of uncertain origin that are located predominantly in the posterior cranial fossa and the spinal cord. Although most hemangioblastomas are sporadic, they are associated with autosomally dominant VHL disease in approximately 25% of cases. The tumors may be solid or cystic, and patients usually present with either focal neurological symptoms or increased intracranial pressure due to obstruction of CSF pathways. Most hemangioblastomas can be cured with surgical resection, and long-term recurrence rates seem to depend on the presence of VHL disease and multicentric lesions. FUTURE AND CONTROVERSIESSection 10 of 11
Future treatment of hemangioblastoma will greatly depend on gaining an understanding of its genetic background. Obviously, if identifying a genetic defect responsible for tumor formation and growth becomes possible, this defect could be reversed and tumor growth could be prevented. Also, finding specific genetic and molecular targets in hemangioblastomas may enable treatment using nonsurgical means, with higher success rates and lower risks of complications. REFERENCESSection 11 of 11
Article Last Updated: Apr 13, 2006 |
